可溶性PD-L1是经典霍奇金淋巴瘤有前景的生物标志物但不反映组织表达
该研究配对收集经典霍奇金淋巴瘤(cHL)患者的组织和血浆样本,分析PD-1、PD-L1、PD-L2及VEGF、CD83水平。结果显示cHL患者血浆PD-L1较健康对照上调并与多项临床参数相关,但血浆PD-L1水平与对应肿瘤组织PD-L1总表达无直接相关性。结论认为PD-L1是有前景的可溶性标志物,但未来将其作为免疫检查点治疗反应预测指标的研究应同时纳入活检和血浆样本。
要点
- cHL患者血浆PD-L1较健康对照上调,且与多项临床参数相关。
- 肿瘤微环境强PD-L1表达可贡献高可溶性PD-L1水平,但血浆与组织PD-L1总表达无直接相关。
- VEGF与PD-1水平在组织和血浆中均呈正相关。
核心结论
- PD-L1是cHL有前景的可溶性生物标志物,但其血浆水平不反映组织总表达。
- 未来以PD-L1预测免疫检查点治疗反应的研究应同时纳入活检和血浆样本。
研究设计与样本
- 收集cHL患者配对的肿瘤组织与血浆样本,检测PD-1、PD-L1、PD-L2及VEGF、CD83水平。
主要发现
- cHL患者血浆PD-L1较健康对照上调,并与多项临床参数相关。
- 肿瘤微环境强PD-L1表达贡献高可溶性PD-L1水平,但血浆PD-L1与对应cHL组织PD-L1总表达无直接相关。
- VEGF与PD-1水平在组织和血浆中均呈正相关。
临床怎么用
- 解读cHL患者血浆PD-L1水平时需注意其不能替代肿瘤组织PD-L1表达检测。
- 评估PD-L1作为免疫检查点治疗预测标志物时应同时采集活检与血浆样本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Individually, tissue and soluble markers involved in the programmed cell death protein 1/programmed death-ligand (PD-1/PD-L) axis have been described as biomarkers with clinical value in classical Hodgkin lymphoma (cHL). In the context of the success of immune checkpoint blockade therapy in cHL, it is interesting to discover whether plasma levels of proteins in the PD-1/PD-L axis are a reflection of expression by the corresponding tissue. Paired tissue and plasma samples of cHL patients were collected and analysed for PD-1, PD-L1 and PD-L2 levels. In addition, vascular endothelial growth factor (VEGF) and CD83, molecules regarded to influence the expression of PD-1, PD-L1 and/or PD-L2, were included. PD-L1 was upregulated in the plasma of cHL patients compared to healthy controls and correlated well with several clinical parameters. Strong PD-L1 expression in the tumour microenvironment contributed to high soluble (s)PD-L1 levels, although there was no direct correlation between plasma PD-L1 levels and total expression of PD-L1 in corresponding cHL tissue. Interestingly, we observed a positive correlation between VEGF and PD-1 levels in both tissue and plasma. In conclusion, although PD-L1 is a promising soluble biomarker in cHL, its levels do not reflect the total tissue expression. Future studies focusing on PD-L1 as a predictor for immune checkpoint treatment response, should include both biopsy and plasma samples.
引用
- Veldman J, Alsada ZND, van den Berg A, et al. Soluble PD-L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma. Br J Haematol. 2021. PMID: 33620088. doi:10.1111/bjh.17362
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。